BioCentury
ARTICLE | Clinical News

Rivastach Patch rivastigmine regulatory update

November 17, 2014 8:00 AM UTC

Ono submitted an application in Japan to amend the label of Rivastach Patch rivastigmine to treat mild to moderate Alzheimer's disease to include an additional dosing regimen in which the initial dose of 9 mg once daily is increased by 1 step to the maintenance dose of 18 mg once daily. This regimen is used outside of Japan. The current Japanese label recommends an initial dose of 4.5 mg once daily, which is increased by 4.5 mg every 4 weeks to an 18 mg maintenance dose. ...